Reported resultsCompany-reported
What was reported
ZUG, Switzerland and BOSTON, May 4, 2026 – CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 4, 2026 · Open the source ↗
What the evidence supports
CRISPR Therapeutics published its results for the period in a press release furnished to the SEC (Form 8-K, Item 2.02).
What remains unknown
Audit status of the figures (results furnished on Form 8-K or 6-K are typically unaudited), and anything about future periods. Any outlook is the company's own projection. Figures and claims are the company's own description and have not been independently verified.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineCRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial ResultsU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 4, 2026 · Open the source ↗
Press release lead paragraphZUG, Switzerland and BOSTON, May 4, 2026 – CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · May 4, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:51 UTC
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.